Knight Therapeutics Inc. (GUD.TO)
CAD 5.21
(-0.19%)
CAD 5.21
(-0.19%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 152.65 Million CAD | -22.05% |
| 2022 | 138.06 Million CAD | 19.62% |
| 2021 | 115.41 Million CAD | 41.28% |
| 2020 | 81.69 Million CAD | 203.48% |
| 2019 | 26.91 Million CAD | 164.03% |
| 2018 | 10.19 Million CAD | 44.63% |
| 2017 | 7.04 Million CAD | 60.57% |
| 2016 | 4.39 Million CAD | 620.85% |
| 2015 | 609 Thousand CAD | 66.7% |
| 2014 | 365.32 Thousand CAD | 0.0% |
| 2013 | - CAD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | 35.66 Million CAD | 15.69% |
| 2024 Q1 | 30.82 Million CAD | 33.45% |
| 2023 Q2 | 37.49 Million CAD | -8.02% |
| 2023 FY | 107.61 Million CAD | -22.05% |
| 2023 Q4 | 23.1 Million CAD | -42.51% |
| 2023 Q3 | 40.18 Million CAD | 7.17% |
| 2023 Q1 | 40.76 Million CAD | 10.5% |
| 2022 Q2 | 38.29 Million CAD | 17.91% |
| 2022 FY | 138.06 Million CAD | 19.62% |
| 2022 Q4 | 36.88 Million CAD | 21.34% |
| 2022 Q3 | 30.4 Million CAD | -20.61% |
| 2022 Q1 | 32.47 Million CAD | 15.19% |
| 2021 Q2 | 28.87 Million CAD | 40.29% |
| 2021 Q1 | 20.58 Million CAD | 2.59% |
| 2021 Q4 | 28.19 Million CAD | -25.34% |
| 2021 FY | 115.41 Million CAD | 41.28% |
| 2021 Q3 | 37.76 Million CAD | 30.81% |
| 2020 Q2 | 22.23 Million CAD | 11.97% |
| 2020 FY | 81.69 Million CAD | 203.48% |
| 2020 Q3 | 19.53 Million CAD | -12.16% |
| 2020 Q4 | 20.06 Million CAD | 2.7% |
| 2020 Q1 | 19.86 Million CAD | 7.47% |
| 2019 Q2 | 2.88 Million CAD | 27.12% |
| 2019 Q1 | 2.27 Million CAD | -32.49% |
| 2019 Q4 | 18.48 Million CAD | 463.41% |
| 2019 FY | 26.91 Million CAD | 164.03% |
| 2019 Q3 | 3.28 Million CAD | 13.61% |
| 2018 FY | 10.19 Million CAD | 44.63% |
| 2018 Q4 | 3.36 Million CAD | 28.84% |
| 2018 Q2 | 1.9 Million CAD | -18.1% |
| 2018 Q1 | 2.32 Million CAD | 12.84% |
| 2018 Q3 | 2.61 Million CAD | 37.42% |
| 2017 Q3 | 1.52 Million CAD | -24.15% |
| 2017 Q2 | 2 Million CAD | 37.35% |
| 2017 Q1 | 1.46 Million CAD | 6.56% |
| 2017 FY | 7.04 Million CAD | 60.57% |
| 2017 Q4 | 2.05 Million CAD | 35.0% |
| 2016 FY | 4.39 Million CAD | 620.85% |
| 2016 Q1 | 822 Thousand CAD | 182.47% |
| 2016 Q4 | 1.37 Million CAD | -14.04% |
| 2016 Q2 | 600 Thousand CAD | -27.01% |
| 2016 Q3 | 1.59 Million CAD | 166.0% |
| 2015 Q3 | 96 Thousand CAD | 57.85% |
| 2015 Q4 | 291 Thousand CAD | 203.13% |
| 2015 FY | 609 Thousand CAD | 66.7% |
| 2015 Q1 | 161.11 Thousand CAD | 46.99% |
| 2015 Q2 | 60.81 Thousand CAD | -62.25% |
| 2014 Q4 | 109.6 Thousand CAD | 1488.29% |
| 2014 Q3 | 6901.00 CAD | -97.21% |
| 2014 Q2 | 247.37 Thousand CAD | 17066.76% |
| 2014 Q1 | 1441.00 CAD | 0.0% |
| 2014 FY | 365.32 Thousand CAD | 0.0% |
| 2013 FY | - CAD | 0.0% |
| 2013 Q3 | 957.81 Thousand CAD | 0.0% |
| 2012 Q3 | 393.24 Thousand CAD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Aurora Cannabis Inc. | 131.46 Million CAD | -16.12% |
| Avicanna Inc. | 6.65 Million CAD | -2192.522% |
| Avant Brands Inc. | 12.43 Million CAD | -1127.896% |
| Cardiol Therapeutics Inc. | -248.35 Thousand CAD | 61565.241% |
| Crescita Therapeutics Inc. | 10.36 Million CAD | -1372.906% |
| MediPharm Labs Corp. | 5.85 Million CAD | -2507.208% |
| OrganiGram Holdings Inc. | 35.07 Million CAD | -335.238% |
| Canopy Growth Corporation | 80.88 Million CAD | -88.734% |
| Willow Biosciences Inc. | -659 Thousand CAD | 23264.188% |
| Auxly Cannabis Group Inc. | 21.27 Million CAD | -617.451% |